Article Text

Download PDFPDF

Dramatic but suspensive effect of interleukin-1 inhibitors for persistent urticarial vasculitis: a French multicentre retrospective study
  1. Thomas Bettuzzi1,
  2. Alban Deroux2,
  3. Marie Jachiet3,
  4. Meryem-Maud Farhat4,
  5. julien wipff5,
  6. Marc Fabre6,
  7. Laurence Bouillet2,
  8. Nora Kramkimel1,
  9. Selim Aractingi1,
  10. Nicolas Dupin1,
  11. Benjamin Terrier7,8
  1. 1 Department of Dermatology, Hôpital Cochin, Paris, France
  2. 2 Department of Internal medicine, Centre Hospitalier Universitaire Grenoble, Michallon Hospital, Grenoble, France
  3. 3 Department of Dermatology, Hôpital Saint-Louis, Paris, France
  4. 4 Department of Internal Medicine, CHRU Lille Pôle Spécialités Médicochirurgicales, Lille, France
  5. 5 Department of Rheumatology, Hopital Cochin, Paris, France
  6. 6 Department of Internal Medicine, Pierre Oudot Hospital of Bourgoin-Jallieu, Bourgoin-Jallieu, France
  7. 7 Department of Internal Medicine, Cochin Hospital, Paris, France
  8. 8 National Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Paris, France
  1. Correspondence to Dr Benjamin Terrier; benjamin.terrier{at}

Statistics from

Urticarial vasculitis (UV) is rare systemic disease characterised by a dermal capillary inflammation responsible of long-lasting urticarial lesions, and sometimes some systemic manifestations.1 2 UV can be separated into two different entities: hypocomplementemic UV (HUV) and normocomplementemic UV (NUV). Treatment of UV depends on the severity of the disease and the occurrence of relapses. In patients refractory to colchicine or dapsone, glucocorticoids (GCs), conventional immunosuppressive agents or rituximab (RTX) can be used,1 2 leading to significant morbidity. Interleukin-1β (IL-1β) inhibitors are biologics mainly used in autoinflammatory diseases.3 We report here a French retrospective multicentr study of patients treated with IL-1β inhibitors for persistent disease despite GCs and/or immunosuppressive agents.

This French retrospective multicentre study was conducted in four departments of Dermatology and Internal Medicine. We included patients with persistent UV to at …

View Full Text


  • Handling editor Josef S Smolen

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.